West to Participate in Upcoming Investor Conferences in September 2025
WSTEXTON, Pa., Aug. 21, 2025 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that it will present at multiple investor conferences in September. Here are the details of the...
WST INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that West Pharmaceutical Services, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
WSTNEW YORK, June 17, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against West Pharmaceutical Services, Inc. (“West” or “the Company”) (NYSE: WST) and certain of its officers.
West Pharmaceutical Services, Inc. (WST) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
WSTBENSALEM, Pa., June 17, 2025 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against West Pharmaceutical Services, Inc. (West or the Company) (NYSE: WST). IF YOU ARE...
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in West Pharmaceutical Services, Inc. of Class Action Lawsuit and Upcoming Deadlines - WST
WSTNEW YORK, June 17, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against West Pharmaceutical Services, Inc. (West or the Company) (NYSE: WST). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or...
How Is The Market Feeling About West Pharmaceutical Servs?
WSTHow Do Investors Really Feel About West Pharmaceutical Servs?
WSTWest Pharmaceutical Defies Doubters: EPS Jumps, Outlook Raised Despite Tariff Drag
WSTWest Pharmaceutical topped Q1 estimates and raised 2025 guidance, citing stronger device demand and improved inventory trends across key markets.
Watching West Pharmaceutical Services; Executive Reportedly Gives Q2 EPS Guidance Of $1.50-$1.55 During Conf Call
WSTWest Pharma CFO Bernard Birkett to Exit in 2025, Successor Search Underway for Seamless Transition
WSTWest Pharmaceutical Servs Lowers FY2025 GAAP EPS Guidance from $5.97-$6.17 to $5.86-$6.06 vs $6.03 Est
WSTWest Pharmaceutical Servs Raises FY2025 Adj EPS Guidance from $6.00-$6.20 to $6.15-$6.35 vs $6.14 Est; Raises FY2025 Sales Guidance from $2.88B-$2.90B to $2.94B-$2.98B vs $2.90B Est
WSTWest Pharmaceutical Servs Q1 Adj. EPS $1.45 Beats $1.23 Estimate, Sales $698.00M Beat $685.84M Estimate
WSTInsights Ahead: West Pharmaceutical Servs's Quarterly Earnings
WSTHow Is The Market Feeling About West Pharmaceutical Servs?
WSTEvercore ISI Group Initiates Coverage On West Pharmaceutical Servs with Outperform Rating, Announces Price Target of $275
WSTKeybanc Maintains Overweight on West Pharmaceutical Servs, Lowers Price Target to $325
WSTWest Pharmaceutical Stock Sinks On Weaker Than Expected 2025 Guidance
WSTWest Pharmaceutical reported Q4 earnings and revenue above expectations but issued a weak 2025 forecast. William Blair reiterated its Outperform rating.
West Pharmaceutical Services Sees FY25 Adj. EPS $6.00-$6.20 vs. $7.44 Est., Revenue $2.875B-$2.905B vs. $3.042B Est.
WSTWest Pharmaceutical Servs Q4 2024 Adj. EPS $1.82 Beats $1.72 Estimate, Sales $748.800M Beat $740.471M Estimate
WSTLooking Into West Pharmaceutical Servs's Recent Short Interest
WSTPeering Into West Pharmaceutical Servs's Recent Short Interest
WSTKeybanc Maintains Overweight on West Pharmaceutical Servs, Lowers Price Target to $400
WSTWest Pharmaceutical Services Shares Slides Post Q1 Results
WSTWest Pharmaceutical Servs: Q1 Earnings Insights
WSTWest Pharmaceutical Servs (NYSE:WST) reported its Q1 earnings results on Thursday, April 28, 2022 at 06:00 AM.
Here's what investors need to know about the announcement.
West Pharmaceutical Servs Raises FY22 EPS Guidance From $9.20-$9.35 To $9.30-$9.45 Vs. $9.28 Est.; Reaffirms FY22 Sales Guidance Range Of $3.05B-$3.075B Vs. $3.07B Est.
WSTWest Pharmaceutical Servs Q1 EPS $2.30 Beats $2.12 Estimate, Sales $720.00M Miss $720.92M Estimate
WST